Ausgewählte Publikationen (EN)
Inhaltsverzeichnis:
Byfavo®
Clinical Trials
Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, Wahidi M, Shojaee S, Tanner NT, Callahan SP, Feldman G, Lorch DG Jr, Ndukwu I, Pritchett MA, Silvestri GA; PAION Investigators. Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy. Chest. 2019 Jan;155(1):137-146. doi: 10.1016/j.chest.2018.09.015. Epub 2018 Oct 4. PMID: 30292760.
Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, Barish CF, Pruitt R, Cash BD, Quirk D, Tiongco F, Sullivan S, Bernstein D. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018 Sep;88(3):427-437.e6. doi: 10.1016/j.gie.2018.04.2351. Epub 2018 Apr 30. PMID: 29723512.
Rex DK, Bhandari R, Lorch DG, Meyers M, Schippers F, Bernstein D. Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial. Dig Liver Dis. 2021 Jan;53(1):94-101. doi: 10.1016/j.dld.2020.10.039. Epub 2020 Nov 23. PMID: 33243567.
Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial – PubMed
Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020 Aug;34(4):491-501. doi: 10.1007/s00540-020-02776-w. Epub 2020 Apr 17. PMID: 32303884.
Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020 Aug;34(4):543-553. doi: 10.1007/s00540-020-02788-6. Epub 2020 May 16. PMID: 32417976.
Giapreza®
Clinical Trials
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. PMID: 28528561.
Angiotensin II for the Treatment of Vasodilatory Shock – PubMed
Leisman DE, Wieruszewski PM, Busse LW, Chawla LS, Hibbert KA, Handisides DR, Khanna AK, Ostermann M, McCurdy MT, Adams CD, Hodges TN, Bellomo R; ATHOS-3 Investigators. An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock. Crit Care. 2025 Feb 19;29(1):81. doi: 10.1186/s13054-025-05311-z. PMID: 39972379; PMCID: PMC11837372.
Chaba A, Zarbock A, Forni LG, Hästbacka J, Korneva E, Landoni G, Pickkers P, Bellomo R. ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL. Shock. 2025 Jan 1;63(1):88-93. doi: 10.1097/SHK.0000000000002481. PMID: 39671552.
Leisman DE, Handisides DR, Busse LW, et al. ACE inhibitors alter response to angiotensin II in vasodilatory shock. Crit Care. 2024;28(1):130.
https://pubmed.ncbi.nlm.nih.gov/38637829/
Leisman DE, Handisides DR, Busse LW, Chappell MC, Chawla LS, Filbin MR, Goldberg MB, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Adams CD, Hodges TN, Bellomo R; ATHOS-3 Investigators. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock. Crit Care. 2024 Apr 18;28(1):130. doi: 10.1186/s13054-024-04910-6. PMID: 38637829; PMCID: PMC11027368.
Leisman DE, Handisides DR, Chawla LS, Albertson TE, Busse LW, Boldt DW, Deane AM, Gong MN, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Thompson BT, Tumlin JS, Adams CD, Hodges TN, Bellomo R. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock. Ann Intensive Care. 2023 Dec 16;13(1):128. doi: 10.1186/s13613-023-01227-5. PMID: 38103056; PMCID: PMC10725390.
Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023 May 5;27(1):175. doi: 10.1186/s13054-023-04446-1. PMID: 37147690; PMCID: PMC10163684.
Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF, Albertson TE. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020 Feb 6;24(1):43. doi: 10.1186/s13054-020-2733-x. PMID: 32028998; PMCID: PMC7006163.
Reviews
Landoni G, Cortegiani A, Bignami E, De Pascale G, Donadello K, Donati A, Grasselli G, Guarracino F, Monti G, Paternoster G, Tritapepe L, Girardis M. The use of angiotensin II for the management of distributive shock: expert consensus statements. J Anesth Analg Crit Care. 2024 Aug 16;4(1):56. doi: 10.1186/s44158-024-00186-y. PMID: 39152516; PMCID: PMC11328364.
Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, Leone M, DePascale G, Pickkers P, Tissieres P, Annoni F, Kotfis K, Landoni G, Zarbock A, Wieruszewski PM, De Backer D, Vincent JL, Bellomo R. The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II. Crit Care. 2024 Nov 26;28(1):389. doi: 10.1186/s13054-024-05123-7. PMID: 39593182; PMCID: PMC11590289.
Xerava®
Clinical Trials
Solomkin J, Evans D, Slepavicius A, et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surg. 2017;152(3):224–232. doi:10.1001/jamasurg.2016.4237
Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis. 2019 Aug 30;69(6):921-929. doi: 10.1093/cid/ciy1029. PMID: 30561562; PMCID: PMC6735687.
Solomkin JS, Sway A, Lawrence K, Olesky M, Izmailyan S, Tsai L. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance. Future Microbiol. 2019 Oct;14:1293-1308. doi: 10.2217/fmb-2019-0135. Epub 2019 Oct 1. PMID: 31570004.
Real World Experience
Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB 3rd, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024 Jan 11;12(1):e0235123. doi: 10.1128/spectrum.02351-23. Epub 2023 Nov 29. PMID: 38018984; PMCID: PMC10782980.
Reviews
Huang PY, Hsu CK, Tang HJ, Lai CC. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. Expert Rev Anti Infect Ther. 2024 Jun;22(6):387-398. doi: 10.1080/14787210.2024.2351552. Epub 2024 May 8. PMID: 38703093.
Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025 Jan 18;405(10474):257-272. doi: 10.1016/S0140-6736(24)02081-6. PMID: 39826970.
Multidrug-resistant Gram-negative bacterial infections – PubMed
In Vitro Studies
Hawser S, Kothari N, Monti F, Morrissey I, Siegert S, Hodges T. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J Glob Antimicrob Resist. 2023 Jun;33:304-320. doi: 10.1016/j.jgar.2023.04.017. Epub 2023 May 18. PMID: 37207925.
In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020 – PubMed
Livermore DM, Mushtaq S, Warner M, Woodford N. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016 May 23;60(6):3840-4. doi: 10.1128/AAC.00436-16. PMID: 27044556; PMCID: PMC4879382.
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii – PubMed